News 01.09.2020 Schlieren (Zurich), Switzerland, September 1, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease. The first patient was...
News 26.08.2020 Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial in vitro and in vivo data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen. Secured partnership with AGC Biologics to meet initial projected...
News 14.08.2020 Swiss biotech company Memo Therapeutics AG (MTx) isolated a highly potent antibody isolated from clinically selected convalescent COVID-19 donors. The selected antibody will undergo an accelerated development program as an immunotherapy and for the prevention of COVID-19. MTx has already concluded a partnership for the production. MTx today announces a collaboration...
News 12.08.2020 Schlieren (Zurich), Switzerland, August 12, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, today reported its results for the first half year 2020. Despite the adverse impact of COVID-19 on elective surgery, Kuros accelerated sales of its lead product MagnetOs, which increased by 42% compared to...
News 11.08.2020 Zurich-Schlieren, Switzerland, August 11, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced the reservation by the Swiss Federal Office of Public Health: Bundesamt für Gesundheit (FOPH-BAG) of a defined number of initial doses...